In this study, we further compared the receptor-ligand and receptor-isoform specificity of estrogen receptor ligands in the modulation of dihydrotestosterone (DHT) actions in prostate cancer cells and endothelial cells, aiming to develop novel therapeutic agents for prostate cancer therapy with minimized cardiovascular side-effects. This evidence concerns the gene ESR1 and prostate cancer.